CN115003302A - 用于治疗分枝杆菌感染的阿莫西林和阿维巴坦衍生物的口服给药组合 - Google Patents

用于治疗分枝杆菌感染的阿莫西林和阿维巴坦衍生物的口服给药组合 Download PDF

Info

Publication number
CN115003302A
CN115003302A CN202080088738.1A CN202080088738A CN115003302A CN 115003302 A CN115003302 A CN 115003302A CN 202080088738 A CN202080088738 A CN 202080088738A CN 115003302 A CN115003302 A CN 115003302A
Authority
CN
China
Prior art keywords
substituted
oxy
alkyl
pharmaceutically acceptable
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080088738.1A
Other languages
English (en)
Chinese (zh)
Inventor
J·特里亚斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arixa Pharmaceuticals
Original Assignee
Arixa Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arixa Pharmaceuticals filed Critical Arixa Pharmaceuticals
Publication of CN115003302A publication Critical patent/CN115003302A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080088738.1A 2019-12-20 2020-12-17 用于治疗分枝杆菌感染的阿莫西林和阿维巴坦衍生物的口服给药组合 Pending CN115003302A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951187P 2019-12-20 2019-12-20
US62/951,187 2019-12-20
PCT/IB2020/062099 WO2021124191A1 (en) 2019-12-20 2020-12-17 Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections

Publications (1)

Publication Number Publication Date
CN115003302A true CN115003302A (zh) 2022-09-02

Family

ID=73856245

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080088738.1A Pending CN115003302A (zh) 2019-12-20 2020-12-17 用于治疗分枝杆菌感染的阿莫西林和阿维巴坦衍生物的口服给药组合

Country Status (8)

Country Link
US (2) US20210186983A1 (https=)
EP (1) EP4076451A1 (https=)
JP (2) JP2021102605A (https=)
KR (1) KR20220114629A (https=)
CN (1) CN115003302A (https=)
AU (1) AU2020405540A1 (https=)
CA (1) CA3164938A1 (https=)
WO (1) WO2021124191A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026065871A1 (zh) * 2024-09-30 2026-04-02 科睿迪(南京)医药科技有限公司 β-内酰胺酶抑制剂及其药物组合物与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CN113614084A (zh) * 2019-03-12 2021-11-05 阿里萨制药公司 阿维巴坦衍生物的晶型

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CN113614084A (zh) * 2019-03-12 2021-11-05 阿里萨制药公司 阿维巴坦衍生物的晶型

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VINCENT DUBÉE ET AL: "β-lactamase inhibition by avibactam in mycobacterium abscessus", 《JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY》, vol. 70, pages 1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026065871A1 (zh) * 2024-09-30 2026-04-02 科睿迪(南京)医药科技有限公司 β-内酰胺酶抑制剂及其药物组合物与应用

Also Published As

Publication number Publication date
US20240245705A1 (en) 2024-07-25
EP4076451A1 (en) 2022-10-26
WO2021124191A1 (en) 2021-06-24
US20210186983A1 (en) 2021-06-24
AU2020405540A1 (en) 2022-06-09
KR20220114629A (ko) 2022-08-17
JP2021102605A (ja) 2021-07-15
CA3164938A1 (en) 2021-06-24
JP2025163188A (ja) 2025-10-28

Similar Documents

Publication Publication Date Title
JP7673052B2 (ja) 細菌感染症を処置するためのベータラクタム抗生物質およびアビバクタム誘導体の経口投与される組合せ
AU2020227077B2 (en) Beta-lactamase inhibitors and uses thereof
AU2020237440B2 (en) Crystalline form of an avibactam derivative
JP2025163188A (ja) マイコバクテリア感染症を治療するための、アモキシシリン誘導体とアビバクタム誘導体の組み合わせ経口投与
HK40083209A (en) Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections
JP7437847B2 (ja) レレバクタムの誘導体およびその使用
RU2825281C1 (ru) Вводимые перорально комбинации бета-лактамных антибиотиков и производных авибактама для лечения бактериальных инфекций
HK40072825A (en) Orally administered combinations of beta lactam antibiotics and avibactam derivatives for treating bacterial infections
HK40063686A (en) Crystalline form of an avibactam derivative
CN101232881A (zh) 双环6-亚烷基-青霉烯B-内酰胺酶抑制剂与β-内酰胺抗生素的组合：广谱抗生素
LU86105A1 (fr) Carbapenemes antibiotiques
RU2815314C2 (ru) Ингибиторы бета-лактамаз и их применение
JPH05194528A (ja) 新規な１−オキサペネム−３−カルボン酸類及びそのβ−ラクタマーゼ阻害薬としての用途
NZ758795B2 (en) Atropine pharmaceutical compositions
NZ758795A (en) Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40083209

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220902

WD01 Invention patent application deemed withdrawn after publication